相似文献
1
A comparative analysis of recurrence risk predictions in ER+/HER2- early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast.使用 NHS 诺丁汉预后指数、PREDICT 和 CanAssist Breast 对 ER+/HER2- 早期乳腺癌的复发风险预测进行比较分析。
Breast Cancer Res Treat. 2022 Nov;196(2):299-310. doi: 10.1007/s10549-022-06729-7. Epub 2022 Sep 10.
2
A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort.CanAssist Breast 在欧洲早期乳腺癌患者队列中的回顾性验证。
Breast. 2022 Jun;63:1-8. doi: 10.1016/j.breast.2022.02.010. Epub 2022 Feb 22.
3
The usefulness of CanAssist Breast over Ki67 in breast cancer recurrence risk assessment.CanAssist Breast 在乳腺癌复发风险评估中的作用优于 Ki67。
Cancer Med. 2023 Jun;12(12):13342-13351. doi: 10.1002/cam4.6032. Epub 2023 May 28.
4
Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.Oncotype DX、PREDICT与诺丁汉预后指数之间的相关性：对早期乳腺癌管理的启示
Cureus. 2020 Apr 6;12(4):e7552. doi: 10.7759/cureus.7552.
5
Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients.基于免疫组织化学的 CanAssist-Breast 试验对激素受体阳性乳腺癌患者远处复发预测的临床验证。
Cancer Med. 2019 Apr;8(4):1755-1764. doi: 10.1002/cam4.2049. Epub 2019 Mar 7.
6
Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham Prognostic Index in patients with invasive breast cancer.乳腺钼靶密度和HER2过表达对浸润性乳腺癌患者诺丁汉预后指数的预后贡献。
BMC Cancer. 2016 Nov 2;16(1):833. doi: 10.1186/s12885-016-2892-y.
7
Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial.CanAssist Breast（CAB）在 TEAM 试验荷兰亚组中的 10 年远处复发风险预测在乳腺癌中的应用。
Breast Cancer Res. 2023 Apr 14;25(1):40. doi: 10.1186/s13058-023-01643-2.
8
Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX.CanAssist Breast 和 Oncotype DX 两种乳腺癌预后检测方法的比较。
Cancer Med. 2020 Nov;9(21):7810-7818. doi: 10.1002/cam4.3495. Epub 2020 Oct 7.
9
CanAssist Breast Impacting Clinical Treatment Decisions in Early-Stage HR+ Breast Cancer Patients: Indian Scenario.CanAssist对早期激素受体阳性乳腺癌患者的临床治疗决策产生影响：印度的情况。
Indian J Surg Oncol. 2021 Apr;12(Suppl 1):21-29. doi: 10.1007/s13193-019-01014-4. Epub 2019 Dec 9.
引用本文的文献
1
CanAssist Breast-based prognostication in low-intermediate estrogen receptor positive (ER) early-stage breast cancer patients helps guide treatment decisions.CanAssist对低中级雌激素受体阳性（ER）早期乳腺癌患者进行基于乳腺的预后评估有助于指导治疗决策。
Ther Adv Med Oncol. 2025 May 24;17:17588359251342218. doi: 10.1177/17588359251342218. eCollection 2025.
2
Comparison of Recurrence Risk Prediction by the CanAssist Breast Test and the PREDICT Online Tool in Early Breast Cancer Patients.CanAssist乳腺检测与PREDICT在线工具对早期乳腺癌患者复发风险预测的比较
Cureus. 2025 Jan 12;17(1):e77356. doi: 10.7759/cureus.77356. eCollection 2025 Jan.
3
Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study.基于光谱学的新型工具在激素受体阳性乳腺癌辅助治疗决策中的性能：一项验证研究。
Breast Cancer Res Treat. 2024 Jun;205(2):349-358. doi: 10.1007/s10549-023-07229-y. Epub 2024 Jan 20.
4
The usefulness of CanAssist Breast over Ki67 in breast cancer recurrence risk assessment.CanAssist Breast 在乳腺癌复发风险评估中的作用优于 Ki67。
Cancer Med. 2023 Jun;12(12):13342-13351. doi: 10.1002/cam4.6032. Epub 2023 May 28.
本文引用的文献
1
A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort.CanAssist Breast 在欧洲早期乳腺癌患者队列中的回顾性验证。
Breast. 2022 Jun;63:1-8. doi: 10.1016/j.breast.2022.02.010. Epub 2022 Feb 22.
2
Validation of CanAssist Breast immunohistochemistry biomarkers on an automated platform and its applicability in tissue microarray.CanAssist乳腺免疫组化生物标志物在自动化平台上的验证及其在组织芯片中的应用
Int J Clin Exp Pathol. 2021 Oct 15;14(10):1013-1021. eCollection 2021.
3
The usefulness of CanAssist breast in the assessment of recurrence risk in patients of ethnic Indian origin.CanAssist 乳腺在评估印度裔患者复发风险中的作用。
Breast. 2021 Oct;59:1-7. doi: 10.1016/j.breast.2021.05.007. Epub 2021 May 28.
4
CanAssist Breast Impacting Clinical Treatment Decisions in Early-Stage HR+ Breast Cancer Patients: Indian Scenario.CanAssist对早期激素受体阳性乳腺癌患者的临床治疗决策产生影响：印度的情况。
Indian J Surg Oncol. 2021 Apr;12(Suppl 1):21-29. doi: 10.1007/s13193-019-01014-4. Epub 2019 Dec 9.
5
Machine Learning Algorithms to Predict Recurrence within 10 Years after Breast Cancer Surgery: A Prospective Cohort Study.预测乳腺癌手术后10年内复发的机器学习算法：一项前瞻性队列研究。
Cancers (Basel). 2020 Dec 17;12(12):3817. doi: 10.3390/cancers12123817.
6
Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX.CanAssist Breast 和 Oncotype DX 两种乳腺癌预后检测方法的比较。
Cancer Med. 2020 Nov;9(21):7810-7818. doi: 10.1002/cam4.3495. Epub 2020 Oct 7.
7
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.肿瘤分析测试指导早期乳腺癌辅助化疗决策：系统评价和经济分析。
Health Technol Assess. 2019 Jun;23(30):1-328. doi: 10.3310/hta23300.
8
Treatment and survival of Asian women diagnosed with breast cancer in New Zealand.新西兰诊断为乳腺癌的亚洲女性的治疗和生存情况。
Breast Cancer Res Treat. 2019 Sep;177(2):497-505. doi: 10.1007/s10549-019-05310-z. Epub 2019 Jun 5.
9
Analytical validation of CanAssist-Breast: an immunohistochemistry based prognostic test for hormone receptor positive breast cancer patients.CanAssist-Breast 的分析验证：一种基于免疫组织化学的激素受体阳性乳腺癌患者预后检测方法。
BMC Cancer. 2019 Mar 20;19(1):249. doi: 10.1186/s12885-019-5443-5.
10
Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients.基于免疫组织化学的 CanAssist-Breast 试验对激素受体阳性乳腺癌患者远处复发预测的临床验证。
Cancer Med. 2019 Apr;8(4):1755-1764. doi: 10.1002/cam4.2049. Epub 2019 Mar 7.
Zotero 插件